×
Geron Operating Expenses 2010-2025 | GERN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Geron operating expenses from 2010 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.
View More
Geron Operating Expenses 2010-2025 | GERN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Geron operating expenses from 2010 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$237.5B
Amgen (AMGN)
$162B
Gilead Sciences (GILD)
$142.8B
Vertex Pharmaceuticals (VRTX)
$120.5B
Bristol Myers Squibb (BMY)
$93.6B
CSL (CSLLY)
$84.5B
GSK (GSK)
$79.6B
Regeneron Pharmaceuticals (REGN)
$59.9B
Alnylam Pharmaceuticals (ALNY)
$44.3B
Argenex SE (ARGX)
$36.7B
BioNTech SE (BNTX)
$26.5B
Royalty Pharma (RPRX)
$20.9B
Insmed (INSM)
$20B
Biogen (BIIB)
$18.6B
Illumina (ILMN)
$16.9B
Incyte (INCY)
$15B
Genmab (GNMSF)
$14.7B
Genmab (GMAB)
$14.3B
Moderna (MRNA)
$12.4B
BioMarin Pharmaceutical (BMRN)
$11.3B
QIAGEN (QGEN)
$11.2B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Ascendis Pharma (ASND)
$10.2B
Exelixis (EXEL)
$9.9B
Bio-Techne Corp (TECH)
$9B
Verona Pharma American Depositary Share (VRNA)
$9B
Exact Sciences (EXAS)
$8.8B
Blueprint Medicines (BPMC)
$8.3B
Roivant Sciences (ROIV)
$7.7B
Legend Biotech (LEGN)
$7.4B